An Early Phase 1 interventional study of Recombinant Human Keratinocyte Growth Factor-2 for Inhalation (Lyophilized Powder) in ARDS (Moderate or Severe) and ARDS (Acute Respiratory Distress Syndrome), sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by Shanghai Zhongshan Hospital · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies in Lymphoma, Follicular with a site in China — 75 open to participants now, 88 under way, 20 of them phase 3. Lymphoma, Follicular · China.
Among the 147 studies in Lymphoma, Follicular with a site in China, this one is the 107th largest by planned enrollment of the 132 interventional ones that give a count, is one of 22 that started in 2026, is one of 20 in phase 1, reaches primary completion later than 22 of the 87 other live ones, and was the 136th registered.
1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →75 of the 147 studies in Lymphoma, Follicular with a site in China are open now. Recruiting first, the newest first:
Guangzhou Lupeng Pharmaceutical Company LTD. · Sites in China
Ages 18+
Merck Sharp & Dohme LLC · Sites in China, United States, Argentina and 11 more countries
Ages 18+
Sinocelltech Ltd. · Sites in China
Ages 18–80
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Sites in China
Ages 18+ · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in China, United States, Argentina and 13 more countries
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 64 · Phase 3 29 · Phase 4 4
First in 2005; this study’s year is marked. 22 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 48 across 1,505 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 93 across the 132 interventional studies, 150 across the 15 observational. Of the 28 that completed or were terminated, 9 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
70 of 147 have an industry lead sponsor. The 10 most frequent:
Shanghai Zhongshan Hospital is the lead sponsor of 654 studies on the registry; 293 are open to participants now.
Shanghai Zhongshan Hospital has 1 study filed under Lymphoma, Follicular — fewer than ten, so there is no comparison to draw.
22 of the studies in Lymphoma, Follicular with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT04224493Phase 3Epizyme, Inc.A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. | 2027-02-13 |
| NCT07558538Shanghai Zhongshan HospitalA Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome | 2026-11-30 |
| NCT06549335Ruijin HospitalZanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL) | 2026-12-01 |
| NCT06756490Sichuan Huiyu Pharmaceutical Co., LtdA Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation | 2026-12-06 |
Add all 22 to your calendar (.ics) → With an account.
Among the 147 studies in Lymphoma, Follicular with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a randomized, blank-controlled, open-label, single-dose, dose-escalation clinical study of rhKGF-2 in patients with ARDS.
The trial is designed with three dose groups (5 mg, 10 mg, and 15 mg), which will be escalated sequentially from the lowest dose group to the highest dose group. Each dose group will enroll 8 subjects, randomized in a 6:2 ratio according to the order of enrollment, to receive either the corresponding dose of rhKGF-2 (6 subjects) or serve as a blank control (2 subjects). Each subject will receive a single dose, administered once via a disposable bronchoscopic catheter.
All subjects will receive the trial intervention on top of standard ARDS treatment (see Concomitant Medications for details). Following the completion of drug administration, subjects will enter a 28-day follow-up period. Outcome measures include adverse events (AE), vital signs, laboratory parameters, oxygenation index (PFR), chest imaging changes, etc., to evaluate the safety, tolerability, and efficacy of the treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The subject fully understands the purpose of the study, as well as the nature, methods, and potential reactions of the drug. The subject voluntarily signs the form to participate in the study and agrees to comply with the requirements of the study protocol. If the subject is unable to provide consent or has limited capacity to consent, consent must be obtained from the subject's legal guardian.
-
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Recombinant Human Keratinocyte Growth Factor-2 for Inhalation (Lyophilized Powder)
Drug: Recombinant Human Keratinocyte Growth Factor-2 for Inhalation (Lyophilized Powder)
Drug: Recombinant Human Keratinocyte Growth Factor-2 for Inhalation (Lyophilized Powder)
The investigational drug will be reconstituted with water for injection to a concentration of 1 mg/mL, and then administered via a single-use bronchoscopic imaging catheter.
Incidence of adverse events (AE) and incidence of adverse drug reactions (ADR);
Time frame: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
Incidence of serious adverse events (SAE)
Time frame: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
Various laboratory test parameters:White blood cell (WBC) count
Unit of measure: 3.5 - 9.5 × 10\^9/L
Time frame: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
Various Laboratory test parameters: Serum creatinine (Cr) level
Unit of measure: 44 -115 μmol/L
Time frame: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
Various laboratory test parameters: Total Bilirubin
Unit of measure: 3.4-20.4 umol /L
Time frame: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
Incidence of airway spasm (increased airway resistance) caused by local drug stimulation
Time frame: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.
Improvement rate of oxygenation indexPaO₂/FiO₂ ratio (PFR)
Time frame: at Day 3 and Day 7
PaO₂/FiO₂ ratio (PFR) and its change from baseline
Time frame: at Day 3, Day 5, and Day 7
Number of days from baseline to first PaO₂/FiO₂ ratio (PFR) > 300 mmHg or liberation from mechanical ventilation for at least 12 consecutive hours
Time frame: From baseline to first PFR > 300 mmHg or liberation from mechanical ventilation for at least 12 consecutive hours
Change from baseline in the Murray Lung Injury Score(LIS).
Score (scale range: 0-4; higher scores indicate more severe lung injury)
Time frame: at Day 7
Change from baseline in Radiographic Assessment of Lung Edema (RALE) score;
Score (scale range: 0-48; higher scores indicate a worse outcome);
Time frame: at Day 3, Day 7, Day 14, and Day 28
Proportion of patients with improvement in ARDS severity grade
Time frame: at Day 7 and Day 14
Proportion of patients with progression in ARDS severity grade
Time frame: at Day 7 and Day 14
All-cause mortality
Time frame: at Day 28
Systemic evaluation measures: Ventilator-free days at Day 28
Ventilator-free days at Day 28 (unit: days; higher scores indicate a better outcome).
Time frame: at Day 28
Systemic evaluation measures: Non-ICU hospital stay days at Day 28
Non-ICU hospital stay days at Day 28 (unit: days; higher scores indicate a better outcome as applicable).
Time frame: at Day 28.
Systemic evaluation measures: Non-hospitalization days at Day 28
Non-hospitalization days at Day 28 (unit: days; higher scores indicate a better outcome).
Time frame: at Day 28
Plan to share: Yes — All IPD that underlie results in a publication.
Supporting information: Informed consent form
Time frame: Sharing will begin within 6 months after article publication.
Access criteria: IPD and supporting information will be avaible to researchers upon reasonable request (e.g. with a practical and meaningful research proposal).
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.
Of 89 non-industry phase 1 interventional studies under Lymphoma, Follicular, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 6 months is below that.
Counting every sponsor, half of 174 studies reached it within 51 months; a quarter within 30 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.